Gilead Sciences, Inc.
Close on Nov 2, 2026Market cap $211.20BP/E –Yield 1.86%
Gilead Sciences Total HCV Franchise by Quarter
Total HCV Franchise (legacy sub-franchise breakout) — Rest of World sales ($M) ($M)
Gilead Sciences Total HCV Franchise: $97M in Q4 2023, down 1.0% from a year earlier. No newer figure appears in the documents we track.
Where the Q4 2023 figure comes from
Calculated from reported figures: Q4 = full year (10-K) − nine months (10-Q)
Source: Form 10-K (filed 2024-02-23) ↗
Reported in Form 10-Q / 10-K Disaggregated Revenue Note & Form 8-K Product Sales Summary.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Total HCV Franchise (legacy sub-franchise breakout) — Rest of World sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q4 2023 | Dec 31, 2023 | 97 | -1.0% | Form 10-K (filed 2024-02-23) ↗ |
| Q3 2023 | Sep 30, 2023 | 93 | -5.1% | Form 10-Q (filed 2023-11-07) ↗ |
| Q2 2023 | Jun 30, 2023 | 98 | +7.7% | Form 10-Q (filed 2023-08-04) ↗ |
| Q1 2023 | Mar 31, 2023 | 99 | -5.7% | Form 10-Q (filed 2023-05-03) ↗ |
| Q4 2022 | Dec 31, 2022 | 98 | +15.3% | Form 10-K (filed 2024-02-23) ↗ |
| Q3 2022 | Sep 30, 2022 | 98 | -11.7% | Form 10-Q (filed 2023-11-07) ↗ |
| Q2 2022 | Jun 30, 2022 | 91 | -29.5% | Form 10-Q (filed 2023-08-04) ↗ |
| Q1 2022 | Mar 31, 2022 | 105 | -10.3% | Form 10-Q (filed 2023-05-03) ↗ |
| Q4 2021 | Dec 31, 2021 | 85 | -11.5% | Form 10-K (filed 2024-02-23) ↗ |
| Q3 2021 | Sep 30, 2021 | 111 | -11.2% | Form 10-Q (filed 2022-11-02) ↗ |
| Q2 2021 | Jun 30, 2021 | 129 | -18.4% | Form 10-Q (filed 2022-08-08) ↗ |
| Q1 2021 | Mar 31, 2021 | 117 | -36.1% | Form 10-Q (filed 2022-05-04) ↗ |
| Q4 2020 | Dec 31, 2020 | 96 | -32.4% | Form 10-K (filed 2023-02-22) ↗ |
| Q3 2020 | Sep 30, 2020 | 125 | – | Form 10-Q (filed 2021-11-03) ↗ |
| Q2 2020 | Jun 30, 2020 | 158 | – | Form 10-Q (filed 2021-08-05) ↗ |
| Q1 2020 | Mar 31, 2020 | 183 | – | Form 10-Q (filed 2021-05-06) ↗ |
| Q4 2019 | Dec 31, 2019 | 142 | – | Form 8-K (exhibit991earningspressrel.htm, filed 2021-02-04) ↗ |
Cite this data
StockData. (2026). Gilead Sciences Total HCV Franchise ($M), quarterly Q4 2019–Q4 2023 [Data set]. Compiled from Gilead Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/gild/kpis/liver-hcv-total-row
See every metric in the Gilead Sciences KPI table. Data updated Oct 29, 2026.